Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-Müllerian hormone

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-Müllerian hormone. / Nielsen, Anna Pors; Korsholm, Anne-Sofie; Lemmen, Josephine G.; Lykke-Sylvest, Randi; Sopa, Negjyp; Nyboe Andersen, Anders.

In: Gynecological Endocrinology, Vol. 32, No. 8, 18.02.2016, p. 625–628.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Nielsen, AP, Korsholm, A-S, Lemmen, JG, Lykke-Sylvest, R, Sopa, N & Nyboe Andersen, A 2016, 'Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-Müllerian hormone', Gynecological Endocrinology, vol. 32, no. 8, pp. 625–628. https://doi.org/10.3109/09513590.2016.1147548

APA

Nielsen, A. P., Korsholm, A-S., Lemmen, J. G., Lykke-Sylvest, R., Sopa, N., & Nyboe Andersen, A. (2016). Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-Müllerian hormone. Gynecological Endocrinology, 32(8), 625–628. https://doi.org/10.3109/09513590.2016.1147548

Vancouver

Nielsen AP, Korsholm A-S, Lemmen JG, Lykke-Sylvest R, Sopa N, Nyboe Andersen A. Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-Müllerian hormone. Gynecological Endocrinology. 2016 Feb 18;32(8):625–628. https://doi.org/10.3109/09513590.2016.1147548

Author

Nielsen, Anna Pors ; Korsholm, Anne-Sofie ; Lemmen, Josephine G. ; Lykke-Sylvest, Randi ; Sopa, Negjyp ; Nyboe Andersen, Anders. / Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-Müllerian hormone. In: Gynecological Endocrinology. 2016 ; Vol. 32, No. 8. pp. 625–628.

Bibtex

@article{7b9115b89c0a4cf4a87d0c56664db17c,
title = "Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-M{\"u}llerian hormone",
abstract = "Corifollitropin, a long-acting follicle-stimulating hormone (FSH) analogue used for in vitro fertilization (IVF), does not allow individualization of dosage, and the ovarian response is similar to around 300 IU of daily recombinant FSH. This has raised concerns about the risk of ovarian hyperstimulation syndrome (OHSS) when used in standard patients. We administered corifollitropin selectively to patients with anticipated low to moderate ovarian response based on antim{\"u}llerian hormone levels in the lower quartile. The end points were oocyte distribution and occurrence of OHSS in women with AMH  ≤15 pmol/L. The study included a cohort of 368 patients treated in 599 cycles. Post hoc the cohort was subdivided according to AMH. With increasing baseline AMH, the number of oocytes increased from a mean of 2.7 (range 0-8 with AMH  <3 pmol/L) to 6.3 (range 0-15 with AMH 10-15 pmol/L) oocytes. Cancellations of retrievals and transfers decreased significantly with increasing AMH. Overall, the ongoing live pregnancy rate per started cycle was 15.2{\%}. None developed OHSS. No cycles were cancelled or needed triggering of ovulation using a GnRH agonist due to risk of OHSS. Selective use of corifollitropin in patients with AMH in the lower quartile is a safe and appropriate way of optimising stimulation.",
author = "Nielsen, {Anna Pors} and Anne-Sofie Korsholm and Lemmen, {Josephine G.} and Randi Lykke-Sylvest and Negjyp Sopa and {Nyboe Andersen}, Anders",
year = "2016",
month = "2",
day = "18",
doi = "10.3109/09513590.2016.1147548",
language = "English",
volume = "32",
pages = "625–628",
journal = "Gynecological Endocrinology",
issn = "0951-3590",
publisher = "Taylor & Francis",
number = "8",

}

RIS

TY - JOUR

T1 - Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-Müllerian hormone

AU - Nielsen, Anna Pors

AU - Korsholm, Anne-Sofie

AU - Lemmen, Josephine G.

AU - Lykke-Sylvest, Randi

AU - Sopa, Negjyp

AU - Nyboe Andersen, Anders

PY - 2016/2/18

Y1 - 2016/2/18

N2 - Corifollitropin, a long-acting follicle-stimulating hormone (FSH) analogue used for in vitro fertilization (IVF), does not allow individualization of dosage, and the ovarian response is similar to around 300 IU of daily recombinant FSH. This has raised concerns about the risk of ovarian hyperstimulation syndrome (OHSS) when used in standard patients. We administered corifollitropin selectively to patients with anticipated low to moderate ovarian response based on antimüllerian hormone levels in the lower quartile. The end points were oocyte distribution and occurrence of OHSS in women with AMH  ≤15 pmol/L. The study included a cohort of 368 patients treated in 599 cycles. Post hoc the cohort was subdivided according to AMH. With increasing baseline AMH, the number of oocytes increased from a mean of 2.7 (range 0-8 with AMH  <3 pmol/L) to 6.3 (range 0-15 with AMH 10-15 pmol/L) oocytes. Cancellations of retrievals and transfers decreased significantly with increasing AMH. Overall, the ongoing live pregnancy rate per started cycle was 15.2%. None developed OHSS. No cycles were cancelled or needed triggering of ovulation using a GnRH agonist due to risk of OHSS. Selective use of corifollitropin in patients with AMH in the lower quartile is a safe and appropriate way of optimising stimulation.

AB - Corifollitropin, a long-acting follicle-stimulating hormone (FSH) analogue used for in vitro fertilization (IVF), does not allow individualization of dosage, and the ovarian response is similar to around 300 IU of daily recombinant FSH. This has raised concerns about the risk of ovarian hyperstimulation syndrome (OHSS) when used in standard patients. We administered corifollitropin selectively to patients with anticipated low to moderate ovarian response based on antimüllerian hormone levels in the lower quartile. The end points were oocyte distribution and occurrence of OHSS in women with AMH  ≤15 pmol/L. The study included a cohort of 368 patients treated in 599 cycles. Post hoc the cohort was subdivided according to AMH. With increasing baseline AMH, the number of oocytes increased from a mean of 2.7 (range 0-8 with AMH  <3 pmol/L) to 6.3 (range 0-15 with AMH 10-15 pmol/L) oocytes. Cancellations of retrievals and transfers decreased significantly with increasing AMH. Overall, the ongoing live pregnancy rate per started cycle was 15.2%. None developed OHSS. No cycles were cancelled or needed triggering of ovulation using a GnRH agonist due to risk of OHSS. Selective use of corifollitropin in patients with AMH in the lower quartile is a safe and appropriate way of optimising stimulation.

U2 - 10.3109/09513590.2016.1147548

DO - 10.3109/09513590.2016.1147548

M3 - Journal article

C2 - 26891977

VL - 32

SP - 625

EP - 628

JO - Gynecological Endocrinology

JF - Gynecological Endocrinology

SN - 0951-3590

IS - 8

ER -

ID: 165080397